Loading...
The FDA is mandating boxed warnings on gadolinium-based MRI contrast agents.
The agency says that patients with severe renal insufficiency who are exposed to the agents are at risk for developing nephrogenic systemic fibrosis, a life-threatening disease that can cause thickening and hardening of the skin, connective tissues, and other organs. Also at risk are patients with chronic liver disease, or with just-transplanted livers, who have any level of renal insufficiency. Several cases of gadolinium-associated fibrosis were reported in February in MMWR.
The FDA advises that physicians should check their patients' renal status before exposure to gadolinium-based agents.
Comment
Link: FDA announcement (Free)
Link: FDA information on gadolinium-containing agents (Free)
Link: Physician's First Watch coverage of MMWR article (Free)